Results 41 to 50 of about 527 (153)

Antibacterial activity of enmetazobactam against <i>Acinetobacter</i> spp.: a molecular dissection of mechanism of action and resistance determinants. [PDF]

Antimicrob Agents Chemother
Báez-Barroso G-A, Rodríguez-Coello A, Vázquez-Ucha JC, López-Argüello S, Outeda-García M, González-Pinto L, García-Pose A, Guijarro-Sánchez P, Alonso-García I, Lence E, González-Bello C, Oliver A, Arca-Suárez J, Moya B, Bou G, Beceiro A, Spanish National Acinetobacter spp. 2020 Study Group.   +16 more
europepmc   +2 more sources

Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics. [PDF]

J Antimicrob Chemother
Nielsen MBD, Mikkelsen MKD, Rasmussen HC, Hvistendahl MA, Lützhøft CH, Slater J, Crocoll C, Poborsky M, Jørgensen NP, Soriano A, Stilling M, Bue M.   +11 more
europepmc   +3 more sources

Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine. [PDF]

JAC Antimicrob Resist
Boral J, Toft N, Baybes AE, Tellapragada C, Nazarchuk O, Fernandez C, Giske C, Riesbeck K.   +7 more
europepmc   +2 more sources

P100 Validation of cefepime/enmetazobactam on Bruker AST devices [PDF]

JAC Antimicrob Resist
Jon Ward, Charlotte Moter, Julia Fritz, Juan Quevedo, Esther Pfeil, Sara M. Klose   +5 more
europepmc   +3 more sources

1477. A Randomized Phase 2 Study of Cefepime Combined with the Novel Extended Spectrum β-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) [PDF]

Journal of Pharmaceutical and Biomedical Analysis, 2019
A simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the simultaneous analysis enmetazobactam (also known as AAI101) and cefepime in human plasma. Sample preparation was based on protein precipitation with acetonitrile. Separation was performed on Acquity BEH HILIC column (50 mm × 
Yehuda Carmeli, Philipp Knechtle, J. Hardenberg, Mathias Knecht   +3 more
openalex   +3 more sources

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam [PDF]

Journal of Clinical Microbiology, 2019
Adam Belley, Michael D Huband, Robert Flamm   +2 more
exaly   +2 more sources

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015 [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered clinical trials to assess safety and efficacy in patients with complicated urinary tract infections.
Ian Morrissey, Sophie Magnet, Stephen Hawser, Stuart Shapiro, Philipp Knechtle   +4 more
openalex   +3 more sources

Penicillanic Acid Sulfones Inactivate the Extended-Spectrum β-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of β-Lactamase Inhibition

mBio, 2022
β-Lactamases hydrolyze β-lactam antibiotics and are major determinants of antibiotic resistance in Gram-negative pathogens. Enmetazobactam (formerly AAI101) and tazobactam are penicillanic acid sulfone (PAS) β-lactamase inhibitors that differ by an ...
Philip Hinchliffe, Catherine L. Tooke, Christopher R. Bethel, Benlian Wang, Christopher Arthur, Kate J. Heesom, Stuart Shapiro, Daniela M. Schlatzer, Krisztina M. Papp-Wallace, Robert A. Bonomo, James Spencer   +10 more
doaj   +1 more source

Reply to Shapiro, “Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales ”

Antimicrobial Agents and Chemotherapy, 2022
International ...
Juan Carlos Vázquez-Ucha, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, Marina Oviaño, Laura Álvarez-Fraga, Isaac Alonso-García, Jorge Arca-Suárez, Germán Bou, Alejandro Beceiro   +8 more
openalex   +6 more sources

Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections [PDF]

, 2021
Introduction Infections due to carbapenem-resistant Gram-negative bacteria (CR-GNB) are increasingly frequent events, which are associated with a high mortality rate.
Bassetti, Matteo, Cenderello, Giovanni, Falletta, Antonio, Giacobbe, Daniele R., Vena, Antonio   +4 more
core   +1 more source